Tonix Pharmaceuticals Holding Balance Sheet Health
Financial Health criteria checks 5/6
Tonix Pharmaceuticals Holding has a total shareholder equity of $105.5M and total debt of $8.9M, which brings its debt-to-equity ratio to 8.4%. Its total assets and total liabilities are $154.5M and $48.9M respectively.
Key information
8.4%
Debt to equity ratio
US$8.91m
Debt
Interest coverage ratio | n/a |
Cash | US$24.95m |
Equity | US$105.53m |
Total liabilities | US$48.93m |
Total assets | US$154.46m |
Recent financial health updates
Recent updates
Tonix stock rises on FDA nod to start trial of TNX-601 for depression
Oct 03Tonix Pharmaceuticals GAAP EPS of -$1.22 beats by $0.23
Aug 08Tonix announces partnership to study monkeypox vaccine in 1H 2023
Jul 28Tonix Pharma to develop extended-release form of depression therapy
Jul 11Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?
Jun 21Financial Position Analysis
Short Term Liabilities: TNXP's short term assets ($47.8M) exceed its short term liabilities ($18.9M).
Long Term Liabilities: TNXP's short term assets ($47.8M) exceed its long term liabilities ($30.0M).
Debt to Equity History and Analysis
Debt Level: TNXP has more cash than its total debt.
Reducing Debt: TNXP's debt to equity ratio has increased from 0% to 8.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TNXP has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: TNXP is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.